China SXT Pharmaceuticals (SXTC) Raw Materials (2021 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Raw Materials for 6 consecutive years, with $276999.0 the latest figure, recorded in Q1 2026.

• Quarterly Raw Materials fell 36.44% year-over-year to $276999.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $276999.0 (down 36.44% YoY) and the FY2026 annual result came in at $276999.0, down 36.44% from the prior year.
• Raw Materials eased to $276999.0 in Q1 2026 per SXTC's latest filing, from $297544.0 in the prior quarter.
• Over the last five years, Raw Materials for SXTC reached as high as $604850.0 in Q1 2022 and fell as low as $192702.0 in Q3 2022.
• A 5-year average of $340083.2 and a median of $309133.0 in 2024 frame the typical range for Raw Materials.
• Annual changes were most pronounced in 2022 — Raw Materials surged 71.26% — and 2023, when it tumbled 59.79%.
• Year by year, Raw Materials stood at $192702.0 in 2022, then increased by 26.22% to $243222.0 in 2023, then surged by 43.42% to $348828.0 in 2024, then declined by 14.7% to $297544.0 in 2025, then dropped by 6.9% to $276999.0 in 2026.
• According to Business Quant data, Raw Materials over the past three periods registered $276999.0, $297544.0, and $435799.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.